key: cord-0831412-j6u9z2ay
authors: Klassen, Stephen A.; Senefeld, Jonathon W.; Johnson, Patrick W.; Carter, Rickey E.; Wiggins, Chad C.; Shoham, Shmuel; Grossman, Brenda J.; Henderson, Jeffrey P.; Musser, James; Salazar, Eric; Hartman, William R.; Bouvier, Nicole M.; Liu, Sean T.H.; Pirofski, Liise-anne; Baker, Sarah E.; van Helmond, Noud; Wright, R. Scott; Fairweather, DeLisa; Bruno, Katelyn A.; Wang, Zhen; Paneth, Nigel S.; Casadevall, Arturo; Joyner, Michael J.
title: The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis
date: 2021-02-17
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2021.02.008
sha: 317513dc4d749e53d30100257756b9e66ca5ca3e
doc_id: 831412
cord_uid: j6u9z2ay

To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials (RCT), 20 matched-control studies, two dose-response studies, and 96 case-reports or case-series. Studies published between January 1, 2020 – January 16, 2021 were identified through a systematic search of online PubMed and MEDLINE databases. Random-effects analyses of RCT and matched-control data demonstrated that COVID-19 patients transfused with convalescent plasma exhibited a lower mortality rate compared to patients receiving standard treatments. Additional analyses showed that early transfusion (within 3 days of hospital admission) of higher-titer plasma is associated with lower patient mortality. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized COVID-19 patients.

Convalescent plasma is a century-old passive antibody therapy that has been used to treat outbreaks of novel infectious diseases, including those affecting the respiratory system. 1, 2 At the onset of the pandemic, human convalescent plasma was used world-wide as it represented the only antibody-based therapy to treat coronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). [2] [3] [4] [5] Despite the emerging availability of monoclonal antibody therapies and vaccines for use in non-hospitalized patients via federal emergency authorization routes, convalescent plasma usage has persisted (~100,000 units/month in the United States in early 2021) during subsequent waves of the COVID-19 pandemic due to surging hospitalizations and mortality rates. [6] [7] [8] [9] However, evidence for therapeutic COVID-19 convalescent plasma efficacy still requires definitive support from large randomized clinical trials (RCT). As a result, there remains a lack of consensus on convalescent plasma use in hospitalized COVID-19 patients. 10, 11 Smaller RCTs, matchedcontrol studies, and case-series studies investigating convalescent plasma therapy for COVID- 19 have emerged and provided a positive efficacy signal. [12] [13] [14] [15] [16] [17] [18] Most of these studies, however, lacked appropriate statistical power or were terminated early. Also, many studies have transfused patients only after clinical progression to severe COVID-19 respiratory distress, which opposes historical data highlighting the efficacy of early convalescent plasma transfusion and overlooks viral neutralization as the fundamental mechanism for convalescent plasma therapy. 1, 2 There is an urgent need to determine the efficacy of potential treatments amidst the ongoing COVID-19 pandemic. Although a 'living' systematic review has summarized a broad-ranging clinical experience with convalescent plasma, 10, 11 this approach may be limited because it employed stringent inclusion criteria for aggregating patient outcomes, which prevented a preliminary assessment of convalescent plasma efficacy. Given the insufficient patient outcome data available from RCTs, we used a pragmatic approach for study selection to aggregate COVID-19 clinical outcomes, focusing solely on mortality data from RCTs, matched-control studies, dose-response investigations, and case-series or case reports in real time. Our primary objective was to derive an aggregate estimate of the mortality rates from transfused and nontransfused cohorts of contemporaneous COVID-19 studies. As an exploratory objective, we assessed whether the time from hospital admission to convalescent plasma transfusion was associated with patient mortality.

We included RCTs, matched-control trials, dose-response studies, and case-series or casereports published on pre-print servers or peer-reviewed journals that investigated the impact of human convalescent plasma therapy on COVID-19 patient mortality.

We performed a systematic search of the online Pubmed and MEDLINE databases from January 1, 2020 through January 16, 2021. Keywords used in the search included: J o u r n a l P r e -p r o o f ((convalescent plasma) OR (convalescent serum)) AND COVID-19 (and medical subject headings; MeSH terms) using the following limits: Humans. No language restrictions were imposed. The references of all eligible studies were reviewed to identify other potentially eligible studies. In order to be considered eligible for inclusion, studies must have: 1) included patients with confirmed diagnosis of COVID-19, 2) used convalescent plasma treatment, and 3) reported mortality. Randomized clinical trials, matched-control studies, dose-response studies, caseseries and case-reports were included. Two reviewers (S.A.K and J.W.S) independently screened the titles and abstracts of all studies identified by the search to determine eligibility. Studies that were deemed potentially eligible had their full text reviewed (S.A.K and J.W.S) in order to determine if they met the criteria for inclusion in the review. Disagreement was resolved by consensus. Two reviewers (S.A.K and J.W.S) extracted study and patient characteristics as well as clinical information (variables delineated in Supplemental Tables S4, S5, S6).

Two reviewers (S.A.K and J.W.S) independently assessed the risk of bias for mortality data of each included study using the Cochrane Risk of Bias criteria (for RCTs) and the Newcastle-Ottawa Scale (for matched-control studies) (Supplement tables S1 and S2). [19] [20] [21] Doseresponse studies were evaluated with the Newcastle-Ottawa Scale. The criteria developed by the Mayo Clinic Evidence-Based Practice Research Program informed our assessment of bias in the mortality data reported by case-series and case-reports. 22 

For RCTs and matched-control studies, we recorded the number of survivors and non-survivors in transfused and non-transfused cohorts to calculate odds ratios with 95% confidence intervals. For dose-response studies, we recorded the number of survivors and non-survivors among patients who were transfused with higher-titer and lower-titer convalescent plasma unit subgroups to calculate odds ratios with 95% confidence intervals. Aggregate mortality rates were calculated for transfused and, if applicable, non-transfused patients at the longest reported vital status for each study.

Using the DerSimonian-Laird random-effects method 23 we computed aggregate odds ratios with 95% confidence intervals separately for RCTs and matched-control studies. We also computed aggregate odds ratios with 95% confidence intervals for RCTs and matched-control studies, combined. Simple random-effects meta-regression analyses evaluated the moderator variables (i.e., cohort age, proportion of cohort receiving mechanical ventilation, and duration of study follow up) on mortality for all clinical studies. The I 2 statistic was used to quantify heterogeneity. Based on historical data, 1 we performed an exploratory subgroup analysis to assess the impact of early transfusion (within 3 days of hospital admission) compared to late transfusion (>3 days after hospital admission) on COVID-19 patient mortality. All analyses were performed with Comprehensive Meta-analysis Software (Biostat, version 3.3.070). Tests were two-tailed and alpha was 0.05. Figures were made with R software (R Core Team). The number needed to treat was calculated using aggregate data from controlled studies. 24 Dose-response studies, case-series and case-reports were not included in the meta-analysis but were described in a narrative.

We used the GRADE approach to assess the certainty of evidence regarding the impact of convalescent plasma on COVID-19 patient mortality. 25 The risk of bias assessments for RCT and matched-control data informed our certainty of evidence assessment.

The literature search yielded 780 studies, of which 128 studies met the eligibility criteria and were included in the systematic review (Supplemental Figure S1 ). The present analyses included a total of 10 RCTs, 13,18,26-33 20 matched-control studies, 16,34-53 two dose-response studies, 54,55 and 96 case-series or case-reports. 3, 15, 40, 46, Overall, these studies reported outcomes from 35,055 COVID-19 patients in 31 countries ( Table 1, Table 2 , and Supplemental Table S3 ). The age of patients enrolled in these studies ranged from 4 to 100 years, with a greater proportion of men than women in most studies (proportion of women: 0% to 100%) (Supplemental Tables S4, S5, S6). All studies included patients with diagnosed COVID-19, with most studies including hospitalized patients with severe or life-threatening COVID-19. At the time of plasma transfusion, the proportion of patients on mechanical ventilation varied by study from 0% to 100%. The duration of follow up ranged from 2 to 118 days (Supplemental Tables S4, S5, S6). In most studies, patients were eligible to receive concomitant and experimental therapies such as antivirals, steroids, and chloroquine or hydroxychloroquine.

When data from the 10 RCTs were aggregated, there was no association between convalescent plasma therapy and mortality (odds ratio [OR]: 0.76, 95% confidence interval [95% CI]: 0.54, 1.09, P = 0.14, I 2 = 7%) ( Table 1 and Figure 1 ). Although the heterogeneity was low, one RCT (Agarwal et al. 32 ) demonstrated a directionally different effect, had a large statistical weight (34.2), and represented the primary source of heterogeneity (ΔI 2 = 7%). Additionally, in the context of COVID-19, neutralizing antibodies are hypothesized to represent the primary active agent in convalescent plasma and the marker of plasma potency. 148, 149 In this regard, as mentioned below, two studies report a dose-response relationship between convalescent plasma antibody level and mortality, suggesting the need for a sufficient amount of antibody for therapeutic success. 148, 149 The Agarwal et al. 32 trial included a large proportion of patients (~70%) in the convalescent plasma arm whom received plasma with low levels of SARS-CoV-2 antibodies less than 1:80, with ~30% receiving plasma with no detectable antibodies. 32 Thus, there were strong analytical and biological rationales to exclude this study from statistical models.

When analyses were performed on data from nine RCTs excluding the Agarwal et al. 32 study, patients transfused with convalescent plasma exhibited a lower mortality rate compared to nontransfused COVID-19 patients (11% vs. 16% mortality; OR: 0.65, 95% CI: 0.43, 0.98, P = 0.04, J o u r n a l P r e -p r o o f I 2 = 0%) ( Table 1 and Figure 1 ). The aggregate OR (0.65) indicates that convalescent plasma was associated with a 35% reduction in the odds of mortality among COVID-19 patients.

When we aggregated mortality data from the 20 matched-control studies, patients transfused with convalescent plasma exhibited a lower mortality rate compared to non-transfused patients (21% vs. 29% mortality; OR: 0.57, 95% CI: 0.45, 0.72, P < 0.001, I 2 = 61%) ( Table 1 and Figure 1 ).

Aggregation of mortality data from all controlled studies including RCTs and matched-control studies indicated that patients transfused with convalescent plasma exhibited a 42% reduction in mortality rate compared to patients receiving standard treatments (20% vs. 28% mortality; OR: 0.58, 95% CI: 0.47, 0.71, P < 0.001, I 2 = 53%) ( Table 1 and Figure 1 ). Simple randomeffects meta-regression analyses indicated that cohort age (P = 0.23), proportion of cohort receiving mechanical ventilation (P = 0.51), and duration of study follow up (P = 0.29) did not affect the aggregate OR computed for all controlled studies.

Sixteen studies (n = 6 RCTs, n = 10 matched-control studies) reported the number of days between hospital admission and convalescent plasma transfusion (Supplemental Table S4 ). Exploratory analysis revealed that the mortality reduction associated with convalescent plasma transfusion was greater in studies that transfused patients within 3 days of hospital admission (OR: 0.44 95% CI: 0.32, 0.61) compared to studies that transfused patients >3 days after hospital admission (OR: 0.79 95% CI: 0.62, 0.98; Random effects test of heterogeneity between subgroups: P = 0.005). However, this analysis was strongly influenced by the study by Altuntas and colleagues 42 which transfused patients >3 days after admission (relative weight: 73%). 

Two studies investigated the association between convalescent plasma antibody levels and the risk of mortality from COVID-19. 3, 55 Although different criteria were used to categorize convalescent plasma units as higher and lower antibody level, both studies found a doseresponse association between antibody level and COVID-19 morality, such that patient mortality was lower in the subgroups transfused with higher-titer plasma. The aggregate mortality rate of COVID-19 patients transfused with higher-titer convalescent plasma was lesser than patients transfused with lower-titer plasma (22% vs. 29% mortality).

The aggregate mortality rate among COVID-19 patients transfused with convalescent plasma reported in uncontrolled studies was 13% (range: 0% to 100%), which is comparable to the mortality rates exhibited by transfused cohorts from clinical trials and matched-control studies (Supplemental Table S3 ). Case-series and case-report data included diverse patient cohorts with varying inherent risk for COVID-19 complications. Several studies explored immunosuppressed patients with suppressed antibody production due to hematological malignancies, cancer-directed therapy, or X-linked agammagloblulinemia (XLA) and provided an important 'experiment of nature' to evaluate convalescent plasma efficacy for COVID-19. 95, 127, 150, 151 For example, Jin et al. 95 highlighted a series of three XLA patients with severe COVID-19 that failed to respond to other supportive treatments but demonstrated strong improvements in oxygen requirements and viral clearance within days of receiving convalescent plasma transfusions.

Overall, we deemed the risk of bias for mortality data to be low-to-moderate for RCTs and lowto-moderate for matched-control studies. We present the full judgement for each study in Supplemental Table S1 and S2. The risk of bias for uncontrolled studies is inherently high. Visual inspection of the funnel plot to assess publication bias shows that one study falls below the 95% CI and two studies fall above the 95% CI (Supplemental Figure S2 ). The funnel plot shows symmetry in the effect sizes among studies with low standard error and asymmetry among studies with greater standard error, suggesting that smaller studies with larger standard error may be more likely to report an effect of convalescent plasma. However, Egger's regression test suggests that there is no significant asymmetry of the plot (intercept = -0.17, P = 0.67).

The certainty in the estimate of the effect of convalescent plasma on mortality is moderate-tohigh. 152 This judgment was based on the consistency of the results between RCT and matchedcontrol studies and the corroborating evidence from dose-response studies and other uncontrolled case data. When aggregating data from all controlled studies, the meta-analyses provided precise estimates, did not demonstrate substantial heterogeneity, and demonstrated no strong evidence of publication bias. The inherent limitations of the included studies rendered the certainty of evidence judgement to be moderate-to-high.

Based on the aggregate OR (0.58, 95% CI: 0.47, 0.71) computed for all controlled studies and the aggregate mortality rate (28%) expressed by non-transfused cohorts among the controlled studies, in order to avoid one death the number needed to be transfused with convalescent plasma rather than only receive the standard of care is 11 (range: 8 -16).

This analysis represents the most current aggregation of mortality data from contemporaneous COVID-19 convalescent plasma studies. The aggregate mortality rate of transfused COVID-19 patients was lower than that of non-transfused COVID-19 patients. Additional analyses demonstrated that early transfusion of high-titer plasma reduces mortality among patients with COVID-19. These results favor the efficacy of convalescent plasma as a COVID-19 therapeutic agent. The primary biological hypothesis for the efficacy of convalescent plasma is antibodymediated SARS-CoV-2 viral neutralization and interference with viral replication, though other biological mechanisms may also contribute to the mitigation of symptoms. 2 The mortality reduction associated with convalescent plasma aligns with similar analyses of historical data from convalescent plasma trials for viral diseases such as the 1918 flu epidemic, 1 severe acute respiratory syndrome, 153 and H1N1 influenza. 154 Our findings are discordant with those of a previous 'living' systematic review, 10, 11 which concluded that there was insufficient evidence to determine the impact of convalescent plasma on all-cause mortality based on only two RCTs, including one prematurely terminated RCT (Li et al. 12 ). This discordance reflects differences in the studies included in the analysis. Our approach was pragmatic and used less stringent study inclusion criteria, allowing for the inclusion of 30 controlled studies, of which a majority found a directionally similar effect of convalescent plasma and our analyses stratified by study design (e.g., RCT and matched-control studies) revealed similar aggregate ORs.

Mechanistic and clinical data support the reduction in mortality associated with convalescent plasma administration. Importantly, convalescent plasma contains SARS-CoV-2 neutralizing antibodies. 155, 156 Convalescent plasma administration increases SARS-CoV-2 clearance in COVID-19 patients 12,34 including immunocompromised individuals, 95, 110, 121, 150 indicating an antiviral effect. Viral neutralization is then posited to reduce the inflammatory response and thus lessen the likelihood that an over-exuberant immune response progresses to lung damage, interference with gas exchange, and death. Additional evidence arising from animal studies shows that administration of human convalescent plasma is protective against SARS-CoV-2 infection. 157, 158 Antibody-mediated interference with viral replication may increase tissue repair and eventually manifest as reduced mortality. In addition, convalescent plasma transfusion is associated with reductions in inflammatory markers, such as chemokines, cytokines and Creactive protein. 127, 159 Concomitant reductions in inflammation and improved gas exchange may underlie the reductions in oxygen requirements associated with convalescent plasma, even in critically ill patients. These findings provide mechanistic evidence for the reduction in mortality observed in patients receiving convalescent plasma.

There are several limitations to this analysis including aggregating mortality data across study populations that varied by: 1) the nation of data origin, 2) timing relative to world-wide progression of the pandemic, 3) clinical diagnostic and treatment algorithms, 4) plasma antibody titer and administration volume, 5) the latency between COVID-19 diagnosis and transfusion, and 6) the duration of follow up after transfusion. Also, we did not consult a librarian when constructing our search terms. However, high-quality evidence from large RCTs remains unavailable and the continuing global health emergency related to COVID-19 necessitated a J o u r n a l P r e -p r o o f practical real-time aggregation of existing mortality data. We note that the reports cited herein include positive results from different countries, suggesting that efficacy is robust across different health systems. Given the safety of convalescent plasma administration in COVID-19 patients, 3,4 the results of this real-time systematic review and meta-analysis provide encouragement for its continued use as a therapy and may have broad implications for the treatment of COVID-19 and design of RCTs. Importantly, many of the patients enrolled in the studies included in the present analyses received convalescent plasma transfusions later in their disease course. In this context, prior to antibiotics and effective vaccinations, convalescent plasma therapy was widely understood to be most efficacious very early in the course of hospitalizations. 2, 160 As a result, our analysis may underestimate the mortality reduction achievable through early administration of high-titer convalescent plasma for COVID-19.

This real-time systematic review and meta-analysis of contemporaneous studies highlights that the mortality rate of transfused COVID-19 patients was lower than that of non-transfused COVID-19 patients and suggests that early transfusion of high-titer plasma represents the optimal use scenario to reduce the risk of mortality among patients with COVID-19. These results favor the efficacy of convalescent plasma as a COVID-19 therapeutic agent. J o u r n a l P r e -p r o o f Forest plot illustrating odds ratios and 95% confidence intervals computed for each study and aggregated for each study type (DerSimonian-Laird random-effects model). Data are separated by study type with randomized clinical trials presented in blue and matched-control studies presented in orange. Odds ratios for each study type are presented in darker hues and the overall odds ratio pooled across all controlled studies is presented in green. Relative study weights are provided. 

Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

The convalescent sera option for containing COVID-19

Safety Update: COVID-19 Convalescent Plasma

Hospitalized Patients

Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Joint Statement: Blood Community Encourages Individuals to Donate Blood, Convalescent Plasma During National Blood Donor Month and Beyond

Emergency Use Authorization (EUA) for emergency use of bamlanivimab for the treatment of mild to moderate COVID-19

Emergency Use Authorization (EUA) for emergency use of Moderna COVID-19 Vaccine

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

Errors in Trial of Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19

Convalescent Plasma for COVID-19. A randomized clinical trial. medRxiv

Treatment of COVID-19 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality

Hospitalized COVID-19 patients treated with Convalescent Plasma in a mid-size city in the midwest

Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study

The therapeutic effectiveness of Convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in hospitals in Baghdad

Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial. medRxiv

RoB 2: a revised tool for assessing risk of bias in randomised trials

Cochrane Handbook for Systematic Reviews of Interventions Version 6

The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis

Methodological quality and synthesis of case series and case reports

Meta-analysis in clinical trials Control Clin Trials

Chapter 15: Interpretting results and drawing conclusions

The therapeutic potential of Convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad

Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. medRxiv

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

Use of convalescent plasma in hospitalized patients with COVID-19: Case series

COVID-19 Convalescent Plasma Treatment of Moderate and Severe Cases of SARS-CoV-2 Infection: A Multicenter Interventional Study

Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients with Coronavirus Disease

Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: a prospective study. medRxiv

EFFECT OF CONVALESCENT PLASMA ON MORTALITY IN PATIENTS WITH COVID-19 PNEUMONIA. medRxiv

Convalescent plasma treatment of severe COVID-19: a propensity scorematched control study

Convalescent plasma antibody levels and the risk of death from covid-19

Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma

Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient

SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation

Clinical Features of COVID-19 in a Young Man with Massive Cerebral Hemorrhage-Case Report

Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies

Clinical Features of Critical Coronavirus Disease 2019 in Children *

Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: The first two cases

Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease

COVID-19 in Liver Transplant Recipients-A Series with Successful Recovery

Coronavirus Disease 2019 Viremia, Serologies, and Clinical Course in a Case Series of Transplant Recipients

Covalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated Tuberculosis

Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery

Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome. Pediatr Blood Cancer

Prone positioning and convalescent plasma therapy in a critically ill pregnant woman with COVID-19

SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma

Extremely Preterm Infant Born to a Mother With Severe COVID-19 Pneumonia

A patient affected by critical COVID-19 pneumonia, successfully treated with convalescent plasma

Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia

Convalescent hyperimmune plasma for chemoimmunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies

First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia

Rapid recovery of taste and smell in a patient with SARS-CoV-2 following convalescent plasma therapy

Treatment of Immunocompromised COVID-19 patients with Convalescent Plasma

Convalescent Plasma in COVID-19. Mortality-Safety First Results of the Prospective Multicenter FALP 001-2020 Trial. medRxiv

A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma

Convalescent plasma therapy in COVID-19 patients

Patient with severe covid-19 treated with convalescent plasma. Pasient med alvorlig covid-19 behandlet med rekonvalesensplasma

Use of COVID-19 Convalescent Plasma as Prophylaxis in a Patient with New Onset ALL

Response to "COVID-19 in persons with haematological cancers

Burton's Agammaglobulinemia and COVID-19

Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan

A retrospective study on the effects of convalescent plasma therapy in 24 patients diagnosed with covid-19 pneumonia in february and march 2020 at 2 centers in wuhan, china

Bronchoalveolar lavage-based COVID-19 testing in patients with cancer

Convalescent plasma therapy for B-cell depleted patients with protracted COVID-19 disease

Convalescent plasma therapy in coronavirus disease 2019: A case report and suggestions to overcome obstacles

Therapeutic plasma exchange followed by convalescent plasma transfusion in critical COVID-19-An exploratory study

Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia. Ann Hepatobiliary-pancreatic Surg

Critical Illness Due to Covid-19: A Description of the Surge in a Single Center in Sioux Falls

Use of convalescent plasma therapy in Eight mild COVID-19 patients. New microbes new Infect

Convalescent plasma therapy: Helpful treatment of COVID-19 in a kidney transplant recipient presenting with severe clinical manifestations and complex complications

Treatment of 6 COVID-19 Patients with Convalescent Plasma. medRxiv

Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma

Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma

Use of convalescent plasma therapy in two covid-19 patients with acute respiratory distress syndrome in Korea

Outcomes of COVID-19-positive kidney transplant recipients: A single-center experience

Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma

Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia

COVID-19 in recent heart transplant recipients: Clinicopathologic features and early outcomes

Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19

Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy

Secondary hemophagocytic lymphohistiocytosis and severe liver injury induced by hepatic SARS-CoV-2 infection unmasking Wilson's disease: balancing immunosuppression

Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19

Initial experience in Mexico with convalescent plasma in COVID-19 patients with severe respiratory failure, a retrospective case series. medRxiv

Incidence and Outcomes of COVID-19 in Kidney and Liver Transplant Recipients With HIV: Report From the National HOPE in Action Consortium

The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report. Case Reports Women's Heal

Atypical course of COVID-19 in patient with Bruton agammaglobulinemia

Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma

A 63-year-old woman with a history of nonhodgkin lymphoma with persistent sars-cov-2 infection who was seronegative and treated with convalescent plasma

Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy

COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma

Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study

Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: A report of 17 patients

Management and Treatment of COVID-19: The Chinese Experience

A case of COVID-19, with cytokine storm, treated by consecutive use of therapeutic plasma exchange followed by convalescent plasma transfusion: A case report

COVID-19 Outbreak and Emerging Management through Pharmaceutical Therapeutic Strategy

Early use of tocilizumab in respiratory failure associated with acute COVID-19 pneumonia in recipients with solid organ transplantation

Cytosorb filter: An adjunct for survival in the COVID-19 patient in cytokine storm? a case report

COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease

Extracorporeal Membrane Oxygenation for COVID-19-Associated Multisystem Inflammatory Syndrome in a 5-year-old

Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia

Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma

Usefulness of Plasma SARS-CoV-2 RNA Quantification by Dropletbased Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient

A special case of COVID-19 with long duration of viral shedding for 49 days

Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients

SARS-CoV-2 and atypical hemolytic uremic syndrome

Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19

Transient Cardiomyopathy in a Patient With Coronavirus Disease-2019

SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency

A case of COVID-19 Convalescent Plasma Donation in Greece: Directed donation for compassionate use in the donor's critically ill father

Convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. medRxiv

Long-term positive severe acute respiratory syndrome coronavirus 2 ribonucleic acid and therapeutic effect of antivirals in patients with coronavirus disease: Case reports

Successful use of COVID-19 convalescent plasma in a patient recently treated for follicular lymphoma

Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines

Inflammatory cytokine depletion in severe coronavirus disease 2019 infectious pneumonia: A case report

Treatment with convalescent plasma for COVID-19 patients in Wuhan

Early experience with COVID-19 and solid organ transplantation at a US high-volume transplant center

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with

Impact of Convalescent Plasma Transfusion (CCP) In Patients With Previous Circulating Neutralizing Antibodies (nAb) to COVID-19. medRxiv

The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series

Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Convalescent Plasma Rescued a Severe COVID-19 Patient with Chronic Myeloid Leukemia Blast Crisis and Myelofibrosis

Successful recovery of COVID-19-associated recurrent diarrhea and gastrointestinal hemorrhage using convalescent plasma

Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19

Updated Evidence to Support the Emergency Use of COVID-19

Convalescent Plasma (as of 9/23/2020)

Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience

Convalescent plasma therapy for B-cell depleted patients with protracted COVID-19 disease

Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency: A systematic review. medRxiv

Clinical practice guidelines: a primer on development and dissemination

Use of convalescent plasma therapy in SARS patients in Hong Kong

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. medRxiv

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment

Nature and dimensions of the systemic hyper-inflammation and its attenuation by convalescent plasma in severe COVID-19

Return to the past: the case for antibody-based therapies in infectious diseases

The authors express their gratitude to convalescent plasma donors.Author contributions: SAK, JWS, MJJ, AC, NSP conceived and designed the study. SAK, JWS, MJJ, PWJ, CCW, REC analyzed the data and performed statistical analyses. All authors reviewed, critically revised and approved the final version of the manuscript.

The authors declare no competing interests.

The data supporting the study findings are available within the paper.Funding: National Heart, Lung, and Blood Institute grant (5R35HL139854, to MJJ), the National Institute of Diabetes and Digestive and Kidney Diseases (5T32DK07352, to JWS and CCW), the Natural Sciences and Engineering Research Council of Canada (PDF-532926-2019, to SAK), the National Institutes of Health (1-F32-HL154320-01 to JWS), the National Institute of Allergy and Infectious Disease (R21 AI145356 and R21 AI152318, to DF; R01 AI1520789, to AC), and the National Heart, Lung, and Blood Institute (R01 HL059842, to AC)